COVID 19 -and Darpa in YEAR 2023

Synthetic Snake Venom in the mRNA Vaccines

Patents Revealing Use of Toxic Metals in the mRNA Vaccines

Dr Bryan Ardis - Detoxification Agents

To Denature and Detoxify Synthetic Snake Venom in the body:
Nicotine, Ivermectin, Vitamin C, NAC, EDTA, Gllutathione,Hydrogen Peroxide, Mucuna Pruriens

( At 1.10 into the video)

Reiner Fuellmich and Viviane Fischer interviewing Karen Kingston Exposing Pfizer Fraud

Vaccines and Darpa

***

Mass Media Forms Our View of Reality

**************************************************************

 

 

David Martin - Follow the Patent Trail

EDTA Therapy - What is in the Blood?

Supporting Documents from the videos

Snakebites and COVID-19: two crises, one research and development opportunity

Summary box

  • Despite inherent differences, Snakebite Envenoming and COVID-19 have much in common in terms of research and development (R&D) challenges and opportunities.
  • Both crises require a diversified portfolio of R&D solutions, ranging from diagnostics to treatments, that can effectively work and be accessible in different resource settings.
  • Collaborative clinical research and streamlined regulatory pathways are critical to accelerate these candidates in the R&D pipeline.
  • Transformative progress is possible with a concerted approach that aligns strong political will, coordinated financing and the needs of the most marginalised communities.      READ MORE

Toxin-like peptides in plasma, urine and faecal samples from COVID-19 patients

Conclusions: The presence of toxin-like peptides could potentially be connected to SARS-CoV-2 infection. Their presence suggests a possible association between COVID-19 disease and the release in the body of (oligo-)peptides almost identical to toxic components of venoms from animals. Their involvement in a large set of heterogeneous extra-pulmonary COVID-19 clinical manifestations, like neurological ones, cannot be excluded. Although the presence of each individual symptom is not selective of the disease, their combination might be related to COVID-19 by the coexistence of the panel of the here detected toxin-like peptides. The presence of these peptides opens new scenarios on the aetiology of the COVID-19 clinical symptoms observed up to now, including neurological manifestations.  READ MORE

 

SARS-like WIV1-CoV poised for human emergence

Significance

The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome (MERS)-CoV highlights the continued risk of cross-species transmission leading to epidemic disease. This manuscript describes efforts to extend surveillance beyond sequence analysis, constructing chimeric and full-length zoonotic coronaviruses to evaluate emergence potential. Focusing on SARS-like virus sequences isolated from Chinese horseshoe bats, the results indicate a significant threat posed by WIV1-CoV. Both full-length and chimeric WIV1-CoV readily replicated efficiently in human airway cultures and in vivo, suggesting capability of direct transmission to humans. In addition, while monoclonal antibody treatments prove effective, the SARS-based vaccine approach failed to confer protection. Together, the study indicates an ongoing threat posed by WIV1-related viruses and the need for continued study and surveillance.

Abstract

Outbreaks from zoonotic sources represent a threat to both human disease as well as the global economy. Despite a wealth of metagenomics studies, methods to leverage these datasets to identify future threats are underdeveloped. In this study, we describe an approach that combines existing metagenomics data with reverse genetics to engineer reagents to evaluate emergence and pathogenic potential of circulating zoonotic viruses. Focusing on the severe acute respiratory syndrome (SARS)-like viruses, the results indicate that the WIV1-coronavirus (CoV) cluster has the ability to directly infect and may undergo limited transmission in human populations. However, in vivo attenuation suggests additional adaptation is required for epidemic disease. Importantly, available SARS monoclonal antibodies offered success in limiting viral infection absent from available vaccine approaches. Together, the data highlight the utility of a platform to identify and prioritize prepandemic strains harbored in animal reservoirs and document the threat posed by WIV1-CoV for emergence in human populations.